Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
February 18, 2021 07:31 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that it will...
Zai Lab Announces Upcoming Presentations in February Investor Conferences
January 28, 2021 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that senior...
Turning Point and Zai Lab Broaden Collaboration
January 11, 2021 06:45 ET
|
Zai Lab Limited; Turning Point Therapeutics, Inc.
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately...
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
January 06, 2021 16:01 ET
|
Zai Lab Limited; argenx
Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each yearZai Lab granted...
Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference
December 30, 2020 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that...
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
December 28, 2020 19:00 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has...
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
December 28, 2020 07:30 ET
|
Zai Lab Limited
- Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties - Zai Lab to...
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
December 16, 2020 20:15 ET
|
Zai Lab Limited
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head...
Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology
December 01, 2020 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the...
Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Cancer
November 10, 2020 19:00 ET
|
Zai Lab Limited
All three efficacy endpoints in the global Phase 2 FIGHT trial met pre-specified statistical significance• Median progression-free survival (PFS) improved from 7.4 months in the placebo arm to 9.5...